Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24212569 | 0.87 | RAF1 (0.39) | RAF1MAPK14MAPTKMT2ATSHR | |
| SCHEMBL29273316 | 0.81 | NOTUM (0.47) | RAF1NOTUMMAPK14MAPTKMT2A | |
| SCHEMBL4062812 | 0.81 | MAPT (0.42) | RAF1NOTUMMAPK14MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL11007849 | 0.80 | IKBKB (0.51) | RAF1NOTUMMAPK14MAPTKMT2A | |
| SCHEMBL833851 | 0.78 | DAO (0.46) | NOTUMMAPTHSD17B10KDM4ELMNA | |
| SCHEMBL24212419 | 0.78 | L3MBTL1 (0.46) | RAF1NOTUMMAPK14MAPTKMT2A | |
| SCHEMBL1969132 | 0.78 | KMT2A (0.51) | RAF1NOTUMMAPK14MAPTKMT2A | |
| SCHEMBL11014523 | 0.76 | MAPT (0.43) | RAF1NOTUMMAPK14MAPTKDM4E | |
| SCHEMBL19439632 | 0.76 | MAPT (0.40) | RAF1NOTUMMAPK14MAPTKMT2A | |
| SCHEMBL6828628 | 0.75 | GSK3B (0.33) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-111629728-A | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | 科尔沃斯制药股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3675856-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | US | disclosed |
| EP-3409671-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| CN-1471533-A | N-([1,2,4] triazoloazinyl) thiophene sulfonamide compounds as herbicides | �ݶ�ũ������˾ | 2004-01-28 | — | — | CN | disclosed |
| US-6645918-B1 | N-(Triazolo(1,5-a)pyrimidinyl)thiophenesulfonamide compounds; postemergence herbicides; agriculture | DOW AGROSCIENCES LLC | 2003-11-11 | — | — | US | disclosed |
| US-20030199393-A1 | N- ([1,2,4,] TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | ARNDT KIM ERIC (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1330458-A1 | N-( 1,2,4]TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AS HERBICIDES | Dow Agrosciences LLC (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6518222-B2 | Prepared from 2-amino(1,2,4)triazolo(1,5-c)pyrimidine, 2-amino(1,2,4)triazolo(1,5-a)pyrimidine, and 2-amino(1,2,4)triazolo(1,5-a)pyridine compounds and thiophenesulfonyl chloride compounds | DOW AGROSCIENCES LLC | 2003-02-11 | — | — | US | disclosed |
| US-20020094935-A1 | N-([1,2,4] triazoloazinyl) thiophenesulfonamide compounds and their use as herbicides | DOW AGROSCIENCES LLC | 2002-07-18 | — | — | US | disclosed |
| WO-2002038572-A1 | N-([1,2,4]TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2002-05-16 | — | — | WO | disclosed |
| US-6121202-A | 2-((THIENYL OR FURYL) (OXY OR THIO))-PYRIDINE AND 6-((THIENYL OR FURYL) (OXY OR THIO))-PYRIMIDINE COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | RAF1 823/4885NOTUM 4817/4885MAPK14 2927/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | RAF1 2560/4885NOTUM 4777/4885MAPK14 4514/4885 |
| US-20020094935-A1 | N-([1,2,4] triazoloazinyl) thiophenesulfonamide compounds and their use as herbicides | PNPO, NAT1, DDT | RAF1 2865/4885NOTUM 1132/4885MAPK14 3118/4885 |
| US-20030199393-A1 | N- ([1,2,4,] TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | NAT1, TST, TASP1 | RAF1 2138/4885NOTUM 673/4885MAPK14 1834/4885 |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | RAF1 823/4885NOTUM 4817/4885MAPK14 2927/4885 |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | RAF1 823/4885NOTUM 4817/4885MAPK14 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.